2023 ESC Guidelines for the management of cardiomyopathies
This guideline cites 4 of the 199 landmark trials in our Cardiology register.
- Issued by
- ESC
- Year
- 2023
- Source
- Arbelo E, Protonotarios A, et al. Eur Heart J. 2023;44(37):3503–3626.doi 10.1093/eurheartj/ehad194
The first dedicated ESC cardiomyopathy guideline introduces a phenotype-based classification spanning HCM, DCM, the new non-dilated left ventricular cardiomyopathy (NDLVC), restrictive and arrhythmogenic right ventricular cardiomyopathy. The register's landmark trials for hypertrophic cardiomyopathy and cardiac amyloidosis are grouped below.
Hypertrophic cardiomyopathy: cardiac myosin inhibitors2
- 2022VALOR-HCMCardiology · HF · myosin inhibitorIn 112 patients with obstructive HCM referred for septal reduction therapy, mavacamten reduced the need to proceed with or remain eligible for septal reduction therapy compared with placebo.17.9% vs 76.8%Read →
- 2020EXPLORER-HCMCardiology · HF · myosin inhibitorIn 251 patients with symptomatic obstructive HCM (NYHA II-III, LVOT gradient ≥50 mmHg), mavacamten improved the composite of peak VO2 and NYHA functional class compared with placebo.37% vs 17%Read →
Cardiac amyloidosis (ATTR)1
- 2018ATTR-ACT CoreCardiology · HF · CardiomyopathyIn 441 patients with transthyretin amyloid cardiomyopathy, tafamidis reduced all-cause mortality and cardiovascular hospitalisation compared with placebo.HR 0.7Read →
Sudden-death prevention (ICD)1
- 2016DANISHCardiology · Arrhythmia · ICDIn 1,116 patients with non-ischaemic heart failure (EF ≤ 35 %), a prophylactic defibrillator did not reduce all-cause mortality compared with usual care.HR 0.87Read →
Published since the guideline2
- 2024SEQUOIA-HCMCardiology · HF · myosin inhibitorIn 282 patients with symptomatic obstructive HCM, aficamten improved peak oxygen uptake on exercise testing compared with placebo.Read →
- 2024ATTRibute-CMCardiology · HF · TTR stabiliserIn 632 patients with transthyretin amyloid cardiomyopathy, acoramidis improved a hierarchical composite of death, CV hospitalisation, NT-proBNP and 6-minute walk distance compared with placebo.WR 1.895% CI 1.4-2.2Read →
Cited landmark trials not yet in the register3
Further landmark trials this guideline cites that are not (yet) covered in our register. Each links out to the study for further reading.
- 2018MAVERICK-HCM
Mavacamten dose-finding in non-obstructive HCM.
- 2024HELIOS-B
Vutrisiran (siRNA) in transthyretin amyloid cardiomyopathy.
- 2023APOLLO-B
Patisiran in transthyretin amyloid cardiomyopathy.
Every trial shown is one this guideline actually cites: each link was checked against the guideline's own reference list, and the few that a machine cannot match, a trial cited through a later follow-up, or a NICE guideline, which carries no DOI, were verified by hand against the full text. This is not the guideline's complete reference list, only the landmark trials it cites that our register holds.